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httpcense.Abstract Aim of the work: To study the maternal and fetal outcomes in pregnant women with
systemic sclerosis (SSc) and to analyze the possible associated risk factors.
Patients and methods: Twenty pregnant women with SSc and 20 age-matched low risk pregnant
women were recruited in this study. Patients were evaluated clinically and in the laboratory at the
entry of the study and at monthly intervals. Different pregnancy outcome measures were studied.
Impacts of pregnancy on scleroderma patients were determined during and after pregnancy. The
possible associated risk factors were analyzed.
Results: Twenty SSc pregnant women were recruited in this study with a mean age of 29.6 ± 3.
Eight (40%) of them had limited SSc, and 12 (60%) had diffuse type. Pregnancies were complicated
by maternal ﬂare of the underlying disease in six (30%) pregnant patients. Six patients (30%) had
preterm labor. Four patients (20%) had small for gestational age (SGA) infants, two of them (10%)
had intra uterine growth retardation (IUGR). Two patients (10%), with diffuse type, fulﬁlled the19413656.
.com (F. Ismail).
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102 F. Ismail et al.criteria of antiphospholipid syndrome (APS) but unfortunately the pregnancy ended in miscarriage.
Eight (40%) full-term infants were born two of them had SGA, two cases with miscarriage due to
renal crisis and pulmonary hypertension and another two cases with intra uterine fetal death
(IUFD). The live birth rate was 14/20 (70%) in the SSc group.
Conclusion: Women with SSc can safely have healthy pregnancies if pregnancy is planned when
the disease is stable and managed by a multidisciplinary team during pregnancy.
 2012 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Systemic sclerosis (SSc) is a systemic, inﬂammatory, autoim-
mune disease affecting the skin and viscera, manifesting path-
ologically with microvascular lesions, perivascular inﬁltration
by mononuclear cells and increased deposition of extracellular
collagen [1]. It affects women of childbearing age at least ﬁve
times more than men [2]. The marked female excess, as well
as the trend for increasing maternal age due to social change
and assisted reproductive technologies, renders heightened sig-
niﬁcance to issues of fertility, pregnancy course and pregnancy
outcomes [1].
Vascular disease in SSc is a major cause of morbidity and
mortality among non-pregnant patients and is an even bigger
concern in the pregnant patient, as the underlying vasculopa-
thy may prevent the required hemodynamic changes necessary
to support a growing pregnancy [3]. Renal crisis remains the
most dreaded complication of a scleroderma pregnancy and
necessitates the prompt institution of angiotensin converting
enzyme (ACE) inhibitor therapy despite its potential teratoge-
nicity [4,5]. In order to minimize the risk for renal crisis; preg-
nancies should be avoided in rapidly progressive diffuse
disease as such patients are at a greater risk for developing seri-
ous cardiopulmonary and renal problems early in the disease
[1]. Of all the vascular complications of SSc, Raynaud’s phe-
nomenon and digital ulcers are most likely to improve during
pregnancy [6,7].
In the past, scleroderma patients were thought to be at high
risk for poor fetal and maternal outcome to the level that they
were strongly advised against pregnancy and often counseled
to terminate pregnancies that have occurred [8,9]. Current ret-
rospective studies showed that despite an increased frequency
of prematurity and small for gestational age infants, overall
maternal and neonatal survival is good [7,10,11]. Hence, at
present, with close monitoring and appropriate therapy most
scleroderma patients can sustain a successful pregnancy [1].
This study was conducted to evaluate the maternal and fetal
outcomes in pregnant women with SSc and to analyze the pos-
sible associated risk factors.
2. Patients and methods
This prospective multi center study was conducted in the El-
Minia and Beni-Suif University Hospitals during the period
from January, 2006 to July, 2012 and after being approved
by the local research committees. During this period, 20 preg-
nant women with SSc and fulﬁlling the criteria of the Ameri-
can College of Rheumatology (ACR), 1997 [12] for the
diagnosis of SSc with a mean age of 29.6 ± 3.4 years were re-
cruited in this study. Another 20 age-matched low riskpregnant women with a mean age of 27.3 ± 2.4 years were
taken as a control group. Detailed counseling and a written in-
formed consent was taken from each patient prior to participa-
tion in this study.
All recruited patients were submitted to clinical and labora-
tory assessment at the start of the study. The following clinical
data were checked; maternal age, parity, disease subtype, dura-
tion of disease, extent of organ involvement, and presence of
skin manifestations especially Raynaud’s phenomenon, gastro-
intestinal tract manifestations, arthralgia or arthritis, cardio-
pulmonary manifestations specially pulmonary hypertension
when the pulmonary artery pressure was >30 Hg at rest [13],
pulmonary ﬁbrosis by using pulmonary function tests, and sero-
sitis (pericardial effusion or pleural effusion) by using echocar-
diography, renal manifestations especially renal crisis, edema
of the lower limbs, measurement of blood pressure and autoan-
tibody status.
Deﬁnitions of limited scleroderma and diffuse scleroderma
were those used by Le Roy et al. [14]. Early disease was deﬁned
arbitrarily as less than 4 years and late disease as more than
4 years of scleroderma symptoms [15], antiphospholipid anti-
body syndrome was diagnosed according to the classiﬁcation
criteria [16].
Laboratory investigations were done at the start of the
study and monthly thereafter. They included: complete blood
count, kidney function tests, urine analysis and liver function
tests. Immunological assessment included: antinuclear anti-
bodies (ANA), anti cardiolipin antibodies (ACL), and Lupus
anticoagulant (LAC). ANA were detected by indirect immuno-
ﬂuorescence using human epithelial cells (Hep-2) as the sub-
strate and ﬂuorescein-conjugated rabbit antihuman Ig (Zeus
Technologies; Cap Bio; La Varenne, France) at an initial dilu-
tion of 1:50 [17], ACL were done by double immunodiffusion
ELISA [18], and ﬁnally lupus anticoagulant test (LAC) [19].
During pregnancy they were treated as a high risk preg-
nancy. They were followed clinically each 2 weeks up to
28 weeks then at weekly intervals up to delivery. Ante-partum
fetal surveillance was performed by ultrasound, color Doppler,
cardiotocography when indicated. Continuous intrapartum fe-
tal monitoring was followed during labor. Clinical and labora-
tory reassessment of all patients was done 6 months after
delivery. During pregnancy, all patients were taking low dose
corticosteroids (Prednisone, 5–10 mg) no other immunosup-
pressant medications were taken. Different pregnancy out-
come measures were analyzed. Impacts of pregnancy on
scleroderma patients were determined during and after preg-
nancy. The possible associated risk factors were analyzed.
Statistical analysis was performed using Student’s t-test and
v2 test where appropriate. p< 0.05 was considered statistically
signiﬁcant. Statistical analysis was performed on the SPSS
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Chicago, IL, USA).3. Results
Twenty pregnant women with SSc and 20 low risk pregnant
women with were recruited in this study. The baseline charac-
teristics of pregnant women with SSc are reported in Table 1.
The difference between the two groups regarding age, parity
and type of pregnancy were not statistically signiﬁcant. Of
all the patients, none was known to be hypertensive, three pa-
tients had a past history of miscarriage and one had an intra
uterine fetal death (IUFD). Of 12 planned pregnant women,
none was known to have pulmonary hypertension, or previous
renal disease except one patient who had a history of pre-
eclampsia while among the six patients with non planned preg-
nancies one patient had a history of pulmonary hypertension,
and another two patients had a history of preeclampsia, three
patients had +ve ACL, one +ve LAC, and two fulﬁlled the
criteria of antiphospholipid syndrome (Table 2).
Regarding the effect of pregnancy on the course of the dis-
ease, 10 women (50%) reported that scleroderma symptoms
were unchanged. Four women (20%) reported improvement
in their symptoms of Raynaud’s phenomenon, and skin thick-
ening. Pregnancies were complicated by maternal ﬂare of the
underlying disease in six (30%) patients. They experienced
ﬂares of arthritis in four (20%), esophageal reﬂux in six
(30%), mal-absorption syndrome in one patient (5%) late in
pregnancy, while pulmonary hypertension in one patient
(5%) who had a history of pulmonary hypertension before
pregnancy and pulmonary ﬁbrosis in one (5%) and renal crisis
two (10%). There were two patients who experienced worsen-
ing and complications ending with miscarriage and IUFD.
They had non planned pregnancy; the ﬁrst patient developed
cough, dyspnea and pulmonary hypertension while the other
patient developed progressive decline in pulmonary function
tests throughout pregnancy with ﬂare of pulmonary ﬁbrosis
and required intravenous cyclophosphamide after delivery.
Pregnancy outcomes were compared between the two
groups, patients and controls and also between types of SSc (Ta-
bles 3 and 4). First trimester miscarriage and preterm labor wereTable 1 Baseline characteristics in pregnant patients with systemic
Characteristic
Type of the disease:
Limited
Diﬀuse
Early
Late
Disease duration (years)
Duration between SSc diagnosis and pregnancy (years)
Raynaud’s phenomenon
GERD
Digital ulcer
Arthralgia
Arthritis
Pulmonary ﬁbrosis
APS
n: Number; SSc: systemic sclerosis; APS: antiphospholipid syndrome; GEsigniﬁcantly frequent in patients than controls. The mean gesta-
tional age in the six preterm infants was 34.3 ± 2.3 weeks’ ges-
tation and mean birth weight was 2250 ± 170 g. Four preterm
infants were admitted to the neonatal intensive care unit, and
all of them survived without complications. Two cases of intra-
uterine fetal death occurred at 31st and 24th weeks of gestation
in patients with early diffuse type (who developed renal crisis)
and late limited type (who associated with pulmonary ﬁbrosis)
respectively (Table 4). No cases of congenital anomalies were re-
ported in this study. Six women (diffuse type three early and two
late, and one late limited scleroderma) had an elevated blood
pressure with normal renal function and were believed to have
mild preeclampsia and resulted in preterm delivery. Only two
patients (10%) with diffuse type (one early and one late) had
antiphospholipid syndrome (APS) andwere treated with aspirin
75 mg daily and subcutaneous heparin 40 mg s/day throughout
their pregnancy as prophylactic measures but unfortunately the
pregnancy ended inmiscarriage in (4 and 6 weeks of pregnancy).
The live birth rate was 14/20 (70%) in SSc group it was 13/14 for
planned pregnancy (those patients had no history of serious vis-
ceral involvement (e.g. pulmonary hypertension, pulmonary
ﬁbrosis, and serositis) and 1/6 for unplanned pregnancy with
statistical difference (p< 0.01), Those two patients of early
and late diffuse type who developed renal crisis in the
12,31 weeks of pregnancy respectively in the form of headache,
dyspnea, edema of lower limbs, and rapid elevation of blood
pressure and serum creatinine and the disease was properly con-
trolled by ACE inhibitors and ended in miscarriage and IUFD
and no congenital anomalies were detected. A patient who
had pulmonary hypertension was of the early diffuse type and
ended in miscarriage in the ﬁrst trimester. Two women with
early, diffuse scleroderma had an elevated BP with normal renal
function and were believed to have preeclampsia and ended in
preterm labor at 35 weeks’ gestation and had persistent hyper-
tension postpartum while another four with preeclampsia (one
with diffuse and three with limited type) improved after labor.
On comparing this outcome with control only two control wo-
men developed preeclampsia and returned normotensive after
labor. The difference was statistically signiﬁcant (p< 0.05) (Ta-
ble 3).
Deliveries were uncomplicated. Ten (50%) women had
tight abdominal skin but it did not interfere with them carryingsclerosis (SSc) (n= 20).
N (%)
8 (40)
12 (60)
12 (60)
8 (40)
5.3 ± 2.7
3.6 ± 1.3
10 (50)
12 (60)
4 (20)
4 (30)
6 (20)
4 (3)
2 (10)
RD: gastroesophageal reﬂux disease.
Table 2 Clinical and demographic data of patients in the two groups.
Variable Study group (n= 20) Control group (n= 20) p value
Maternal age
Mean (years) 29.6 ± 3.4 27.3 ± 2.4
Range (years) 20–40 22–42 NS
Parity
PG 8 (40%) 6 (30%)
MG 12 (60%) 14 (70%) NS
Type of pregnancy
Planned 14 (70%) 18 (90%)
Unplanned 6 (30%) 2 (10%) NS
Blood pressure
Systolic (mm Hg) 132 ± 5.5 128 ± 5.2 NS
Diastolic (mm Hg) 81 ± 3.4 73 ± 4.2 NS
Creatinine (mg/dl) 0.92 ± 0.02 0.87 ± 0.1 NS
ANA (+ve) 8 (40%) - -
LAC (+ve) 1 (5%) - -
ACL IgG GPL U (+ve) 3 (15%) - -
n: Number; PG: Primigravida; MG: Multigravida; ANA: Antinuclear antibody; LAC: Lupus anticoagulant; ACL: Anticardiolipin; NS: non
signiﬁcant.
Table 3 Pregnancy outcomes in the two groups; systemic sclerosis (study group) and the control group.
Variable Study group (n= 20) Control group (n= 20) p value
Preeclampsia 6 (30%) 1 (5%) <0.05
GA at delivery (w) 37 ± 1.2 38 ± 1.7 NS
Neonatal birth weight (g) 2542 ± 746 3125 ± 346 NS
Preterm infants 6 (30%) 2 (10%) <0.05
Term infants 8 (40%) 13 (65%) <0.05
IUGR 2 (10%) 2 (10%) NS
Miscarriages 4 (20%) 1 (5%) <0.05
SGA 4 (20%) 2 (10%) NS
IUFD 2 (10%) 0 NS
n: Number; GA: gestational age; SGA: Small for gestational age; IUGR: intrauterine fetal growth restriction; IUFD: intrauterine fetal death; p:
probability; NS: non signiﬁcant.
104 F. Ismail et al.pregnancies to term or having vaginal deliveries. Six women
(30%) had cesarean deliveries because of different obstetric
indications [histories of cesarean delivery (two), failure of
labor to progress (one), cephalic pelvic disproportion (one),
and ﬁnally emergency for preeclampsia (two)]. None of the
women who had cesarean deliveries had problems with healing
or infections.
After delivery, six (30%) of the patients noticed no
changes in their symptoms. Six (30%) women noticed
improvement in esophageal reﬂux and arthritis. Eight
patients (40%) had increased severity of their symptoms
including Reynaud’s phenomenon eight (40%), digital ulcer-
ations two (10%) and skin thickening six (30%). The women
who had skin thickening after pregnancy had diffuse sclero-
derma and stabilized soon after the reinstitution of their
medications.
The association of different clinical and laboratory features
to pregnancy outcome measures is analyzed using Logistic
regression analysis (Table 5). It is obvious that diffuse disease,
renal crisis and LAC were signiﬁcant predictors of miscarriage;
LAC, and ACL were predictors of IUFD while pulmonary
ﬁbrosis was a signiﬁcant risk factor for preterm labor.4. Discussion
Systemic sclerosis is a connective tissue disease of unknown
origin that is characterized by cutaneous and visceral ﬁbrosis,
production of auto-antibodies, and prominent microvascular
changes [20]. It affects women approximately ﬁve times more
than men with a mean age of onset in the mid-forties [21].
The reported outcomes of pregnancies in women with SSc
have been quite variable. There are case reports of concomitant
pregnancy and SSc that resulted in negative outcomes to the
mother or the baby [22–24]. In the absence of signiﬁcant visceral
vasculopathy, most women with SSc can expect to have reason-
able pregnancy outcomes [1]. This result is in agreementwith our
results regarding pregnancy outcome in planned pregnancywith
a live birth rate of 13/14 and 1/6 in non planned pregnancy.
In this study, scleroderma-related symptoms during preg-
nancy were stable in 50% of patients, improved in 20% of pa-
tients (Raynaud’s phenomenon and skin thickening) and
maternal ﬂare was reported in 30% of patients. This is mostly
in agreement with those reported by Steen [15]. Raynaud’s phe-
nomenon tends to improve during pregnancy particularly with
the increased cardiac output in the second half of pregnancy
Table 5 Logistic regression analysis of the risk factors for unfavorable fetal outcome.
Variable Disease duration Diﬀuse SSc Limited SSc PH PF Renal crisis LAC ACL
r p r p r p r p r p r p r p r p
Miscarriage 0.19 NS 0.31 0.01 0.14 NS 0.13 NS 0.1 NS 0.36 0.01 0.23 0.05 0.1 NS
IUFD 0.15 NS 0.29 NS 0.18 NS 0.26 NS 0.21 NS 0.3 NS 0.40 0.001 0.41 0.001
IUGR 0.18 NS 0.15 NS 0.9 NS 0.39 0.01 0.12 NS 0.15 NS 0.17 NS 0.12 NS
Preterm 0.18 NS 0.32 0.01 0.19 NS 0.1 NS 0.42 0.001 0.18 NS 0.32 NS 0.20 NS
SSc: systemic sclerosis; PH: pulmonary hypertension; PF: pulmonary ﬁbrosis; IUGR: intrauterine fetal growth restriction; IUFD: intrauterine
fetal death; LAC: lupus anticoagulant; ACL: anti-cardiolipin; NS: non signiﬁcant; p: probability.
Table 4 Pregnancy outcomes in diffuse and limited systemic sclerosis (SSc) patients.
SSc (n= 20) Term infants (n= 8) Preterm infants (n= 6) IUGR (n= 2) IUFD (n= 2) SGA (n= 4) Miscarriages (n= 4)
Early diﬀuse (n= 7) 3 3 – 1 2 1
Late diﬀuse (n= 5) – 2 1 – – 3
Early limited (n= 5) 4 – – 1 –
Late limited (n= 3) 1 1 1 1 1 –
SGA: Small for gestational age; IUGR: intrauterine fetal growth restriction; IUFD: intrauterine fetal death.
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esophageal reﬂux reported in this studymay be explained by the
pressure of the gravid uterus [15]. After delivery, scleroderma
symptoms increased as Raynaud’s phenomenon eight (40%),
digital ulceration two (10%) and skin thickening six (30%). This
is in agreement with those reported by previous study [15].
Pregnancies were complicated by maternal ﬂare of the
underlying disease in six (30%) patients. They experienced
ﬂares of arthritis, esophageal reﬂux, mal-absorption syndrome,
pulmonary hypertension and renal crisis. Pulmonary hyperten-
sion is a serious complication and is associated with 50%
maternal mortality. Screening should be done before preg-
nancy, and termination should be offered if this complication
is diagnosed in pregnancy [6]. Limitation of diaphragmatic
breathing may exacerbate pre-pregnancy symptoms of dyspnea
[15]. In concordance with the previous studies we reported one
case who developed pulmonary hypertension during preg-
nancy and she was not planned for pregnancy and unfortu-
nately pregnancy ended in miscarriage and the condition was
controlled within 3 weeks after that.
Renal crisis is difﬁcult to diagnose and treat during preg-
nancy as it presents as an acute onset of severe hypertension,
edema of the lower limbs with anemia and daily increase of
serum creatinine in women who have had diffuse scleroderma
for less than 5 years, which mimics preeclampsia. Elevated li-
ver function tests, which should be normal in renal crisis,
and serum creatinine, which increases daily in renal crisis,
are the best ways to differentiate between it and preeclampsia
[25]. Despite the association of ACE inhibitors with birth de-
fects and infant kidney dysfunction, they must be used ur-
gently in renal crisis because they are the only drugs that
successfully control hypertension in renal crisis and the only
lifesaving treatment [26].
In this study we reported two patients of early and late dif-
fuse type who developed renal crisis in the 12th and 31st weeks
of pregnancy respectively. Trying to balance the risks of prob-
lems for infants from the use of ACE inhibitors and the risks of
serious kidney damage in the mother if they are not used canbe difﬁcult. Therefore, the use of these drugs should be re-
stricted to instances of suspected or frank SRC in which their
profound beneﬁt deﬁnitely outweighs the possible risk of fetal
toxicity. Women with scleroderma should be encouraged to
delay pregnancy until their disease has stabilized and the risk
of renal crisis is less, which is usually 3–5 years from the onset
of symptoms [26].
Increased numbers of miscarriages have been reported in
several series [22–24,15,25–27] before [28] and after the onset
of disease [29]. In this study, four cases (20%) of miscarriage
were reported mainly in patients with long standing diffuse
scleroderma who had APS two cases and one pulmonary
hypertension while the 4th case was of early diffuse type due
to progressive pulmonary ﬁbrosis.
The frequency of miscarriage was higher in patients than
controls and diffuse disease, renal crisis and LAC were
signiﬁcant predictors of miscarriage. Decreased blood ﬂow
early in pregnancy might have contributed to the miscar-
riages [3].
Preterm labor was more frequent in scleroderma pregnan-
cies than in controls (30% versus 10%, p< 0.05). Most pre-
term births occurred in women with diffuse scleroderma 5/6
and pulmonary ﬁbrosis was a signiﬁcant risk factor. Given
the diffuse vasculopathy present in patients with SSc, there
are concerns that the same pathophysiologic changes may oc-
cur in the placental vasculature. The higher rates of prematu-
rity and small for gestation babies may be a direct result of
placental vascular insufﬁciency [3].
All pregnant women with scleroderma should be monitored
particularly closely and taught how to recognize early signs of
labor so their physicians can try to delay delivery or prepare
their infants for early birth [15,30].
In our study, LAC and ACL were predictors of IUFD.
Chakravarty et al. concluded that placental abnormalities
may be present in SSc pregnancies even in the absence of clin-
ical perinatal complications and these abnormalities may be
more signiﬁcantly correlating with perinatal growth restriction
and death [3].
106 F. Ismail et al.In conclusion, women with SSc can safely have healthy
pregnancies if pregnancy is planned when the disease is stable
and managed by a multidisciplinary team during pregnancy.
This study has limitations in terms of small sample size. A
large prospective multicenter study is recommended to better
evaluate the pregnancy outcomes in pregnant women with
SSc and to determine the risk factors associated with adverse
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